Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cephalon Revises Fentora Labeling To Highlight Patient Selection Criteria Following Deaths

This article was originally published in The Pink Sheet Daily

Executive Summary

Among the deaths associated with the breakthrough cancer pain treatment were two patients prescribed the drug for migraines, Cephalon tells “The Pink Sheet” DAILY.

You may also be interested in...



Cephalon’s Fentora sNDA Gets FDA Advisory Panel Review

Company tells “The Pink Sheet” DAILY advisory committee meeting slated for May 6 is routine for schedule II opioids.

Cephalon’s Fentora sNDA Gets FDA Advisory Panel Review

Company tells “The Pink Sheet” DAILY advisory committee meeting slated for May 6 is routine for schedule II opioids.

Cephalon Submits Fentora sNDA For Chronic Pain

Application includes strengthened risk management plan to ensure appropriate patient use and dosing, a critical concern after deaths were reported following unapproved uses.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066599

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel